⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MRK News
Merck & Co., Inc.
Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Earlier Stages of Disease at ESMO 2025
businesswire.com
MRK
Merck Completes Acquisition of Verona Pharma
businesswire.com
MRK
VRNA
Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases
businesswire.com
MRK
Merck to Hold Third-Quarter 2025 Sales and Earnings Conference Call Oct. 30
businesswire.com
MRK
FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA ® (pembrolizumab)
businesswire.com
MRK
Advancing Cancer Research Brings New Hope for Patients Worldwide
prnewswire.com
IOVA
MRK
AZN
BMY
Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
businesswire.com
MRK
Merck Manuals Helps Patients Navigate the Different Types of Sunscreens
prnewswire.com
MRK
LUNGevity Foundation Launches Every Breath Forward℠ to Advance Progress and Improve Lives Nationwide
prnewswire.com
BIIB
AZN
JNJ
AMGN
LLY
MRK
REGN
Veterinary Implants Devices Market worth $0.98 billion by 2031 - Exclusive Report by MarketsandMarkets™
prnewswire.com
MRK
ELAN
JNJ
ZTS
HBIO